Apogee Therapeutics rises after Q1 2026 results and pipeline update issued May 11
Apogee Therapeutics reported first-quarter 2026 financial results and provided pipeline progress on May 11, 2026. The update reiterated upcoming APEX Phase 2 Part B 16-week data expected in Q2 2026 and guided Phase 3 initiation in atopic dermatitis later in 2026, alongside a $1.3B cash position.
1. What happened today (May 11, 2026)
Apogee Therapeutics released a company update that combined first-quarter 2026 financial results with pipeline progress, published May 11, 2026. The release highlighted ongoing development of zumilokibart across indications and reiterated key upcoming milestones, which can act as a same-day catalyst for shares.
2. Key pipeline and milestone takeaways
The update emphasized planned Phase 3 initiation for atopic dermatitis later in 2026 and pointed to APEX Phase 2 Part B 16-week data expected in Q2 2026. It also noted that additional trial details for expansion in asthma and eosinophilic esophagitis are expected later in 2026.
3. Financial runway headline
Apogee reported a strong cash position of about $1.3B as of March 31, 2026, and stated this extends runway into 2029 (through planned BLA filing for atopic dermatitis, subject to regulatory alignment).